Dicoumarol antithrombotics

Description Results NMA

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Deaths from any cause 1.00 [0.24; 4.18]

Vascular deaths 1.00 [0.24; 4.18]

Symptomatic intracranial haemorrhage NaN [NaN; NaN]

Major extracranial haemorrhage NaN [NaN; NaN]

Non-fatal stroke/intracranial haemorrhage or vascular death 0.73 [0.54; 1.00]

Major extracranial haemorrhage 10.51 [2.50; 44.16]

Recurrent ischaemic/unknown stroke 0.56 [0.26; 1.20]

Symptomatic intracranial haemorrhage 2.23 [0.58; 8.51]

Any recurrent stroke or symptomatic intracranial haemorrhage 0.63 [0.36; 1.08]

Myocardial infarction 0.76 [0.31; 1.90]

dicumarol, TP 15 to 25% of normal (n=-9)

vs.

placebo (n=-9)

single-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 1 year

heparin 50 mg 4-hourly iv then dicumarol, Quick test 15% to 25% of control (n=-9)

vs.

placebo (n=-9)

single-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 13 months